Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases

Table 2

Medication regimens.

Medication regimen, N (%)	Total DKA	EuDKA	hDKA
SGLT2i only	0 (0%)	0 (0%)	0 (0%)
SGLT2i + metformin	1 (3.45%)	0 (0%)	1 (6.7%)
SGLT2i + thiazolidinedione	1 (3.45%)	1 (7.1%)	0 (0%)
SGLT2i + GLP1 agonist	1 (3.45%)	1 (7.1%)	0 (0%)
SGLT2i + sulfonylurea	1 (3.45%)	0 (0%)	1 (6.7%)
SGLT2i + 2 agents	10 (34.5%)	5 (35.7%)	5 (33.3%)
SGLT2i + ≥3 agents	4 (13.8%)	3 (21.5%)	1 (6.7%)
SGLT2i + insulin ± other agents	11 (37.9%)	4 (28.6%)	7 (46.6%)